HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

BioAge Labs, Inc.

Contributing Author

Recent Articles by BioAge Labs, Inc.

May-08
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates BIOA GlobeNewswire
May-04
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 BIOA GlobeNewswire
Apr-21
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP BIOA GlobeNewswire
Apr-13
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference BIOA GlobeNewswire
Mar-24
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 BIOA -13.53% GlobeNewswire
Feb-19
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference BIOA GlobeNewswire
Jan-21
BioAge Announces Pricing of Upsized $115.0 Million Public Offering BIOA -6.06% GlobeNewswire
Jan-20
BioAge Announces Proposed Public Offering BIOA +5.75% GlobeNewswire
Jan-20
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 BIOA +5.75% GlobeNewswire
Jan-12
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk BIOA +27.23% GlobeNewswire
Dec-04
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA +13.88% GlobeNewswire
Nov-25
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference BIOA GlobeNewswire
Nov-07
BioAge Labs to Present at Jefferies Global Healthcare Conference in London BIOA GlobeNewswire
Nov-06
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Aug-20
BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
Aug-15
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Aug-06
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Jun-21
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions BIOA GlobeNewswire
Jun-17
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank BIOA GlobeNewswire
Jun-03
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BIOA GlobeNewswire
May-29
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic BIOA GlobeNewswire
May-27
BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-06
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)